Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Seoyoung Catherine Kim, Sc.D., M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Seoyoung Kim and Sebastian Schneeweiss.
Seoyoung Kim
Connection Strength
9.691
Sebastian Schneeweiss
  1. When Randomized Clinical Trials and Real-World Evidence Say the Same: Tocilizumab and Its Cardiovascular Safety. Arthritis Rheumatol. 2020 01; 72(1):4-6.
    View in: PubMed
    Score: 0.852
  2. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study. Semin Arthritis Rheum. 2019 10; 49(2):222-228.
    View in: PubMed
    Score: 0.805
  3. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. Semin Arthritis Rheum. 2018 12; 48(3):399-405.
    View in: PubMed
    Score: 0.753
  4. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study. Arthritis Rheumatol. 2017 06; 69(6):1154-1164.
    View in: PubMed
    Score: 0.708
  5. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs. Am J Med. 2015 May; 128(5):539.e7-17.
    View in: PubMed
    Score: 0.601
  6. Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout. Arthritis Care Res (Hoboken). 2013 Dec; 65(12):2008-14.
    View in: PubMed
    Score: 0.559
  7. Validation of claims-based algorithms for identification of high-grade cervical dysplasia and cervical cancer. Pharmacoepidemiol Drug Saf. 2013 Nov; 22(11):1239-44.
    View in: PubMed
    Score: 0.550
  8. Accuracy of identifying neutropenia diagnoses in outpatient claims data. Pharmacoepidemiol Drug Saf. 2011 Jul; 20(7):709-13.
    View in: PubMed
    Score: 0.468
  9. Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease. Gut. 2022 Apr 06.
    View in: PubMed
    Score: 0.249
  10. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Ann Intern Med. 2022 01; 175(1):W4-W5.
    View in: PubMed
    Score: 0.245
  11. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Ann Intern Med. 2021 11; 174(11):1528-1541.
    View in: PubMed
    Score: 0.240
  12. Emulation of a randomized controlled trial in ulcerative colitis with US and French claims data: Infliximab with thiopurines compared to infliximab monotherapy. Pharmacoepidemiol Drug Saf. 2022 02; 31(2):167-175.
    View in: PubMed
    Score: 0.240
  13. Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases. JAMA Dermatol. 2021 07 01; 157(7):805-816.
    View in: PubMed
    Score: 0.236
  14. Calibrating Real-World Evidence Studies Against Randomized Trials: Treatment Effectiveness of Infliximab in Crohn's Disease. Clin Pharmacol Ther. 2022 01; 111(1):179-186.
    View in: PubMed
    Score: 0.235
  15. Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults. Diabetes Care. 2021 03; 44(3):826-835.
    View in: PubMed
    Score: 0.229
  16. Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022 02; 20(2):314-324.e16.
    View in: PubMed
    Score: 0.228
  17. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis. 2019 04; 78(4):456-464.
    View in: PubMed
    Score: 0.200
  18. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ. 2018 02 06; 360:k119.
    View in: PubMed
    Score: 0.187
  19. Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Rheumatoid Arthritis: A Cohort Study. Arthritis Rheumatol. 2016 09; 68(9):2106-13.
    View in: PubMed
    Score: 0.169
  20. Tumor Necrosis Factor-a Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis. Epidemiology. 2016 May; 27(3):414-22.
    View in: PubMed
    Score: 0.165
  21. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. Am J Med. 2015 Jun; 128(6):653.e7-653.e16.
    View in: PubMed
    Score: 0.152
  22. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. Ann Rheum Dis. 2015 Nov; 74(11):1968-75.
    View in: PubMed
    Score: 0.145
  23. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis. 2015 Jul; 74(7):1360-7.
    View in: PubMed
    Score: 0.142
  24. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013 Oct; 65(10):1600-7.
    View in: PubMed
    Score: 0.138
  25. Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Med Res Methodol. 2012 Nov 26; 12:180.
    View in: PubMed
    Score: 0.130
  26. No differences in cancer screening rates in patients with rheumatoid arthritis compared to the general population. Arthritis Rheum. 2012 Oct; 64(10):3076-82.
    View in: PubMed
    Score: 0.129
  27. Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study. J Bone Miner Res. 2012 Apr; 27(4):789-96.
    View in: PubMed
    Score: 0.124
  28. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res. 2011 May; 26(5):993-1001.
    View in: PubMed
    Score: 0.117
  29. Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther. 2010; 12(4):R154.
    View in: PubMed
    Score: 0.111
  30. Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents. JAMA Netw Open. 2022 Apr 01; 5(4):e226567.
    View in: PubMed
    Score: 0.062
  31. Validation of obesity-related diagnosis codes in claims data. Diabetes Obes Metab. 2021 12; 23(12):2623-2631.
    View in: PubMed
    Score: 0.060
  32. Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study. Alzheimers Dement (N Y). 2020; 6(1):e12095.
    View in: PubMed
    Score: 0.057
  33. Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study. J Am Acad Dermatol. 2021 Feb; 84(2):300-311.
    View in: PubMed
    Score: 0.056
  34. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020 08 25; 370:m2812.
    View in: PubMed
    Score: 0.056
  35. Risk of Inflammatory Arthritis After a New Diagnosis of Hidradenitis Suppurativa. JAMA Dermatol. 2020 03 01; 156(3):342-345.
    View in: PubMed
    Score: 0.054
  36. Fracture Risk After Initiation of Use of Canagliflozin. Ann Intern Med. 2019 07 02; 171(1):80.
    View in: PubMed
    Score: 0.051
  37. Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis. JAMA Intern Med. 2019 06 01; 179(6):741-749.
    View in: PubMed
    Score: 0.051
  38. Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study. Ann Intern Med. 2019 02 05; 170(3):155-163.
    View in: PubMed
    Score: 0.050
  39. Association of Medicare's Bundled Payment Reform With Changes in Use of Vitamin D Among Patients Receiving Maintenance Hemodialysis: An Interrupted Time-Series Analysis. Am J Kidney Dis. 2018 08; 72(2):178-187.
    View in: PubMed
    Score: 0.048
  40. Patients' perception about risks and benefits of antithrombotic treatment for the prevention of venous thromboembolism (VTE) after orthopedic surgery: a qualitative study. BMC Musculoskelet Disord. 2015 Oct 26; 16:319.
    View in: PubMed
    Score: 0.040
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.